Instil Bio, Inc. SEC filings TIL
Instil Bio, Inc. has 248 filings in SEC EDGAR's recent list, going back to Sep 30, 2019. Its latest annual report, Form ARS, was filed on Apr 24, 2026 for the period ended Dec 31, 2025. The latest quarterly report (Form 10-Q) was filed on Aug 13, 2026, covering the quarter ended Jun 30, 2026. The most recent current report (Form 8-K) was filed on Aug 13, 2026 (results of operations). The company's fiscal year ends on December 31.
| Form | Description | Filed | Period |
|---|---|---|---|
| 10-Q | Quarterly report | Aug 13, 2026 | Jun 30, 2026 |
| 8-K |
Current report
Results of operations
|
Aug 13, 2026 | Aug 13, 2026 |
| 8-K |
Current report
Shareholder vote results
|
Jun 11, 2026 | Jun 11, 2026 |
| 10-Q | Quarterly report | May 15, 2026 | Mar 31, 2026 |
| 8-K |
Current report
Results of operations
|
May 15, 2026 | May 15, 2026 |
| ARS | Annual report to shareholders | Apr 24, 2026 | Dec 31, 2025 |
| DEFA14A | Additional proxy material | Apr 24, 2026 | — |
| DEF 14A | Proxy statement | Apr 24, 2026 | Jun 11, 2026 |
| 8-K |
Current report
Auditor change
|
Apr 3, 2026 | Apr 1, 2026 |
| S-8 | Employee stock plan registration | Mar 27, 2026 | — |
| 10-K | Annual report | Mar 27, 2026 | Dec 31, 2025 |
| 8-K |
Current report
Results of operations
|
Mar 27, 2026 | Mar 27, 2026 |
| 8-K |
Current report
Agreement ended
|
Jan 6, 2026 | Jan 5, 2026 |
| 10-Q | Quarterly report | Nov 13, 2025 | Sep 30, 2025 |
| 8-K |
Current report
Results of operations
|
Nov 13, 2025 | Nov 13, 2025 |
| 10-Q | Quarterly report | Aug 13, 2025 | Jun 30, 2025 |
| 8-K |
Current report
Results of operations
|
Aug 13, 2025 | Aug 13, 2025 |
| 8-K |
Current report
Other events
|
Jul 31, 2025 | Jul 31, 2025 |
| 8-K |
Current report
Shareholder vote results
|
May 28, 2025 | May 28, 2025 |
| 8-K |
Current report
Regulation FD disclosure, Other events
|
May 27, 2025 | May 22, 2025 |
| 8-K |
Current report
Regulation FD disclosure
|
May 22, 2025 | May 22, 2025 |
| 10-Q | Quarterly report | May 13, 2025 | Mar 31, 2025 |
| 8-K |
Current report
Results of operations
|
May 13, 2025 | May 13, 2025 |
| DEFR14A | Filing | May 2, 2025 | — |
| ARS | Annual report to shareholders | Apr 14, 2025 | Dec 31, 2024 |
| DEFA14A | Additional proxy material | Apr 14, 2025 | — |
| DEF 14A | Proxy statement | Apr 14, 2025 | May 28, 2025 |
| 424B5 | Prospectus supplement | Mar 31, 2025 | — |
| 8-K |
Current report
Material agreement
|
Mar 31, 2025 | Mar 28, 2025 |
| S-8 | Employee stock plan registration | Mar 4, 2025 | — |
| 10-K | Annual report | Mar 4, 2025 | Dec 31, 2024 |
| 8-K |
Current report
Results of operations, Regulation FD disclosure
|
Mar 4, 2025 | Mar 4, 2025 |
| 8-K |
Current report
Other events
|
Jan 14, 2025 | Jan 14, 2025 |
| 8-K |
Current report
Material agreement, Agreement ended, New debt
|
Dec 23, 2024 | Dec 20, 2024 |
| EFFECT | Filing | Nov 21, 2024 | — |
| CORRESP | Letter to the SEC | Nov 19, 2024 | — |
| UPLOAD | Letter from the SEC | Nov 19, 2024 | — |
| S-3 | Shelf registration | Nov 13, 2024 | — |
| 10-Q | Quarterly report | Nov 13, 2024 | Sep 30, 2024 |
| 8-K |
Current report
Results of operations
|
Nov 13, 2024 | Nov 13, 2024 |
| 8-K |
Current report
Regulation FD disclosure, Other events
|
Sep 16, 2024 | Sep 16, 2024 |
| 8-K |
Current report
Exit or restructuring costs
|
Sep 6, 2024 | Sep 1, 2024 |
| 8-K |
Current report
Regulation FD disclosure
|
Aug 15, 2024 | Aug 15, 2024 |
| 10-Q | Quarterly report | Aug 13, 2024 | Jun 30, 2024 |
| 8-K |
Current report
Results of operations
|
Aug 13, 2024 | Aug 13, 2024 |
| 8-K |
Current report
Material agreement
|
Aug 1, 2024 | Aug 1, 2024 |
| 8-K |
Current report
Material agreement
|
Jul 11, 2024 | Jul 10, 2024 |
| 8-K |
Current report
Shareholder vote results
|
Jun 17, 2024 | Jun 13, 2024 |
| 10-Q | Quarterly report | May 10, 2024 | Mar 31, 2024 |
| 8-K |
Current report
Results of operations
|
May 10, 2024 | May 10, 2024 |
| ARS | Annual report to shareholders | Apr 26, 2024 | Dec 31, 2023 |
| DEFA14A | Additional proxy material | Apr 26, 2024 | — |
| DEF 14A | Proxy statement | Apr 26, 2024 | Jun 13, 2024 |
| 8-K |
Current report
Officer or director change
|
Apr 26, 2024 | Apr 24, 2024 |
| S-8 | Employee stock plan registration | Mar 21, 2024 | — |
| 10-K | Annual report | Mar 21, 2024 | Dec 31, 2023 |
| 8-K |
Current report
Results of operations
|
Mar 21, 2024 | Mar 21, 2024 |
| 8-K |
Current report
Officer or director change
|
Feb 14, 2024 | Feb 12, 2024 |
| 8-K |
Current report
Other events
|
Jan 18, 2024 | Jan 17, 2024 |
| 8-K |
Current report
Exit or restructuring costs, Other events
|
Jan 16, 2024 | Jan 14, 2024 |
| 8-K |
Current report
Bylaw or fiscal year change
|
Dec 8, 2023 | Dec 7, 2023 |
| 8-K |
Current report
Regulation FD disclosure
|
Nov 27, 2023 | Nov 21, 2023 |
| 10-Q/A | Amended quarterly report | Nov 13, 2023 | Sep 30, 2023 |
| 10-Q | Quarterly report | Nov 13, 2023 | Sep 30, 2023 |
| 8-K |
Current report
Results of operations
|
Nov 13, 2023 | Nov 13, 2023 |
| 10-Q | Quarterly report | Aug 14, 2023 | Jun 30, 2023 |
| 8-K |
Current report
Results of operations
|
Aug 14, 2023 | Aug 14, 2023 |
| 8-K |
Current report
Other events
|
Jun 26, 2023 | Jun 26, 2023 |
| 8-K |
Current report
Shareholder vote results
|
Jun 14, 2023 | Jun 14, 2023 |
| 10-Q | Quarterly report | May 11, 2023 | Mar 31, 2023 |
| 8-K |
Current report
Results of operations
|
May 11, 2023 | May 11, 2023 |
| DEFR14A | Filing | Apr 28, 2023 | — |
| ARS | Annual report to shareholders | Apr 24, 2023 | Dec 31, 2022 |
| DEFA14A | Additional proxy material | Apr 24, 2023 | — |
| DEF 14A | Proxy statement | Apr 24, 2023 | Jun 14, 2023 |
| PRE 14A | Preliminary proxy statement | Apr 14, 2023 | Jun 14, 2023 |
| 10-K | Annual report | Mar 31, 2023 | Dec 31, 2022 |
| 8-K |
Current report
Results of operations
|
Mar 31, 2023 | Mar 31, 2023 |
| 8-K |
Current report
Other events
|
Mar 10, 2023 | Mar 10, 2023 |
| 8-K |
Current report
Officer or director change
|
Feb 27, 2023 | Feb 22, 2023 |
| 8-K |
Current report
Exit or restructuring costs
|
Feb 1, 2023 | Jan 30, 2023 |
| 8-K |
Current report
Listing notice
|
Jan 27, 2023 | Jan 24, 2023 |
| 8-K |
Current report
Other events
|
Jan 9, 2023 | Jan 9, 2023 |
| 8-K |
Current report
Exit or restructuring costs, Officer or director change
|
Dec 8, 2022 | Dec 2, 2022 |
| 10-Q | Quarterly report | Nov 14, 2022 | Sep 30, 2022 |
| 8-K |
Current report
Results of operations
|
Nov 14, 2022 | Nov 14, 2022 |
| 8-K |
Current report
Other events
|
Nov 8, 2022 | Nov 8, 2022 |
| 8-K |
Current report
Other events
|
Oct 31, 2022 | Oct 26, 2022 |
| 8-K |
Current report
Other events
|
Oct 18, 2022 | Oct 18, 2022 |
| 8-K |
Current report
Officer or director change, Other events
|
Sep 6, 2022 | Sep 2, 2022 |
| 10-Q | Quarterly report | Aug 12, 2022 | Jun 30, 2022 |
| 8-K |
Current report
Results of operations
|
Aug 12, 2022 | Aug 12, 2022 |
| 8-K |
Current report
Material agreement, New debt
|
Jun 13, 2022 | Jun 13, 2022 |
| 8-K |
Current report
Other events
|
May 27, 2022 | May 27, 2022 |
| 8-K |
Current report
Shareholder vote results
|
May 20, 2022 | May 20, 2022 |
| 8-K |
Current report
Other events
|
May 18, 2022 | May 18, 2022 |
| 8-K |
Current report
Results of operations
|
May 16, 2022 | May 16, 2022 |
| 10-Q | Quarterly report | May 16, 2022 | Mar 31, 2022 |
| S-3ASR | Automatic shelf registration | Apr 1, 2022 | — |
| DEFA14A | Additional proxy material | Mar 31, 2022 | — |
| DEF 14A | Proxy statement | Mar 30, 2022 | May 20, 2022 |
| 10-K | Annual report | Mar 7, 2022 | Dec 31, 2021 |
| 8-K |
Current report
Results of operations
|
Mar 7, 2022 | Mar 7, 2022 |
| 8-K |
Current report
Officer or director change
|
Dec 17, 2021 | Dec 17, 2021 |
| 8-K |
Current report
Other events
|
Nov 15, 2021 | Nov 15, 2021 |
| 10-Q | Quarterly report | Nov 15, 2021 | Sep 30, 2021 |
| 8-K | Current report | Nov 15, 2021 | Nov 15, 2021 |
| 8-K |
Current report
Other events
|
Sep 16, 2021 | Sep 16, 2021 |
| 8-K |
Current report
Other events
|
Sep 13, 2021 | Sep 13, 2021 |
| 10-Q | Quarterly report | Aug 12, 2021 | Jun 30, 2021 |
| 8-K |
Current report
Results of operations
|
Aug 12, 2021 | Aug 12, 2021 |
| 8-K |
Current report
Results of operations
|
May 13, 2021 | May 13, 2021 |
| 10-Q | Quarterly report | May 13, 2021 | Mar 31, 2021 |
| 8-K |
Current report
Other events
|
Apr 27, 2021 | Apr 27, 2021 |
| S-8 | Employee stock plan registration | Apr 20, 2021 | — |
| 8-K |
Current report
Other events
|
Apr 13, 2021 | Apr 12, 2021 |
| 8-K |
Current report
Bylaw or fiscal year change
|
Mar 23, 2021 | Mar 23, 2021 |
| 424B4 | Prospectus | Mar 22, 2021 | — |
| EFFECT | Filing | Mar 18, 2021 | — |
| SEC STAFF LETTER | Filing | Mar 18, 2021 | — |
| CERT | 8a cert | Mar 18, 2021 | — |
| S-1/A | Amended registration statement | Mar 18, 2021 | — |
| CORRESP | Letter to the SEC | Mar 16, 2021 | — |
| CORRESP | Letter to the SEC | Mar 16, 2021 | — |
| 8-A12B | Filing | Mar 15, 2021 | — |
| CORRESP | Letter to the SEC | Mar 15, 2021 | — |
| S-1/A | Amended registration statement | Mar 15, 2021 | — |
| UPLOAD | Letter from the SEC | Mar 12, 2021 | — |
| SEC STAFF LETTER | Filing | Mar 8, 2021 | — |
| CORRESP | Letter to the SEC | Mar 8, 2021 | — |
| CORRESP | Letter to the SEC | Feb 26, 2021 | — |
| S-1 | Registration statement | Feb 26, 2021 | — |
| UPLOAD | Letter from the SEC | Feb 24, 2021 | — |
| D | Filing | Feb 23, 2021 | — |
| DRSLTR | Filing | Feb 12, 2021 | — |
| DRS/A | Filing | Feb 12, 2021 | — |
| UPLOAD | Letter from the SEC | Feb 5, 2021 | — |
| DRS | Filing | Jan 12, 2021 | — |
| D | Filing | Aug 5, 2020 | — |
| D | Filing | Aug 5, 2020 | — |
| D/A | Filing | Aug 5, 2020 | — |
| D | Filing | Sep 30, 2019 | — |
Showing 142 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.
New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.
Company profile
- Industry
- Biological Products, (No Diagnostic Substances) (SIC 2836)
- Listed as
- TIL (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- NY
- Headquarters
- Dallas, TX
- SEC filer status
- Non-accelerated filer, Smaller reporting company, Emerging growth company
- SEC CIK
- 1789769
Other Biological Products, (No Diagnostic Substances) companies
- Amgen Inc AMGN
- Gilead Sciences, Inc. GILD
- Moderna, Inc. MRNA
- Argenx SE ARGX
- Revolution Medicines, Inc. RVMD
- Biogen Inc. BIIB
- BioNTech SE BNTX
- Exelixis, Inc. EXEL
All 182 Biological Products, (No Diagnostic Substances) companies
Source: SEC EDGAR filings. This is company-reported data, not investment advice.